YP1 Stock Chart & Stats
€0.31
<€0.01(0.63%)
At close: 4:00 PM EDT
€0.31
<€0.01(0.63%)
Day’s Range― - ―
52-Week Range€3.64 - €58.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€29.94M
Enterprise Value€14.45
Total Cash (Recent Filing)€68.88M
Total Debt (Recent Filing)€1.05M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Feb 25, 2027EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.70
Shares Outstanding7,370,551
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.44
Price to Sales (P/S)6.23
P/FCF Ratio-1.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.74
Revenue Forecast (FY)€2.41M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross-margin RecoveryThe sharp improvement in revenue and gross margin indicates stronger business activity and a more favorable revenue mix. If sustained through clinical and partnering milestones, this progress could improve funding capacity and provide a stronger base for future commercialization.
Low LeverageMinimal debt limits solvency pressure and avoids a substantial interest burden while Immutep funds clinical development. This balance-sheet flexibility gives management more room to pursue programs, negotiate partnerships, and manage financing decisions without heavy creditor constraints.
Proprietary LAG-3 PlatformA proprietary LAG-3 technology platform provides a focused scientific foundation across multiple immuno-oncology and immunotherapy programs. A shared mechanism can support follow-on combinations, partnering opportunities, and portfolio expansion if clinical evidence validates the approach.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means Immutep is consuming capital to maintain development activities rather than funding them internally. Continued deterioration increases the likelihood of additional external financing and limits flexibility if trials or partnerships take longer to mature.
Large And Widening LossesRevenue and gross margin gains have not yet translated into operating profitability, as substantially higher research and development spending drove wider losses. This limits earnings visibility and means the company remains dependent on successful development outcomes to build sustainable economic value.
Shrinking Equity BaseThe substantial reduction in shareholders’ equity reflects the cumulative effect of ongoing losses and indicates that capital is being consumed faster than it is replenished. This weakens financial resilience and may increase future reliance on equity funding, with potential dilution implications.
YP1 FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was €3.64 and its highest was €58.40 in the past 12 months.
What is Immutep’s market cap?
Immutep’s market cap is €29.94M.
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Feb 25, 2027 which is in 145 days.
How were Immutep’s earnings last quarter?
Currently, no data Available
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Overvalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -0.63.
How many shares outstanding does Immutep have?
Immutep has 7,370,551 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Immutep?
Currently, no hedge funds are holding shares in DE:YP1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:YP1 Sentiment 100%
Sector Average 65%
Sector Average 65%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immutep
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Technical Analysis
Cellectis SA
―
Cartesian Therapeutics
―
―
Silence Therapeutics
―
Lyell Immunopharma
―